Durham drug developer Viamet Pharmaceuticals filed initial paperwork for a public offering.
According to the initial filing with the Securities and Exchange Commission, Viamet proposes to raise a maximum of $75 million, though that figure is estimated only to determine a registration fee and will likely change by time Viamet completes the initial public offering.
Help employers find you! Check out all the jobs and post your resume.
